**EXHIBIT      10.1**

**MARKETING,      SALES and DISTRIBUTION AGREEMENT**

**WITNESSETH**

**WHEREAS**

**WHEREAS**

**WHEREAS**

**NOW      THEREFORE**

| **1.** | **APPOINTMENT                AND ACCEPTANCE** |
|--------|-----------------------------------------------|

|   | 1.1. | CI                hereby appoints DOLIAGE as CI's exclusive partner in the Territory.                Exclusive partner in this Section 1.1 shall mean (i) that CI grants                DOLIAGE the exclusive right to promote, market, sell and distribute                the                Products in the Territory under CI's Brand name(s) and Trademark(s)                and                that (ii) that CI shall not appoint any other party than DOLIAGE                to                promote, market, sell and distribute the Products in the                Territory |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.2. | CI                hereby grants DOLIAGE rights, without the right to sublicense, to                use CI's                patents, listed in Schedule A within the Territory for the sole purposes                of carrying out DOLIAGE's obligations under this AGREEMENT. DOLIAGE                agrees                to exercise these rights only as are necessary to meet its obligations                to                promote, market, sell or distribute the Products in the Territory                under                this Agreement. DOLIAGE agrees not use these rights to promote, market,                sell or distribute competitive product(s) within the Territory. CI                agrees                not to grant rights under the patents listed in Schedule A which                would                allow a competitor to promote, market, sell or distribute a competing                medical device for the treatment of primary open angle glaucoma or                ocular                hypertension within the Territory. Passive sales by other distributors                within the Territory and sales on part of the customers of CI shall                not be                restricted by this provision |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**____________**

**Confidential      treatment has been requested with respect to certain portions of this      exhibit. Omitted portions have been filed separately with the Securities and      Exchange Commission.  This exhibit omits the information subject to the      confidentiality request. Omissions are designated as [ *      ].**

 

----

|   | 1.3. | DOLIAGE                accepts such appointment and agrees to use its commercially reasonable                efforts to promote, develop and increase sales of the Products within                the                Territory. Without limiting the generality of the foregoing, DOLIAGE                shall: |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.1. | develop                and distribute to the best advantage of the Products such literature                and                other advertising material as may be agreed to by CI and will not                use or                release any advertising or promotional materials (including, without                limitation, labels, packages, circulars, and advertisements) without                the                prior approval of CI. The consent of CI shall not be unreasonably                withheld. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.2. | solicit                prospective purchasers who may specify or utilize the                Products; |
|--------|--------|-------------------------------------------------------------------------------------------------------|

|   | 1.3.3. | shall                not promote or sell any other product or other product lines which                are a                medical device indicated in the non-surgical treatment of primary                open                angle glaucoma or ocular                hypertension. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.4. | take                no action which might impair the goodwill or reputation of CI or                any of                its affiliated companies or of the                Products; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.5. | refrain                from making quotations or writing letters under the name of CI or                any of                its affiliates. The name of CI or its subsidiaries shall not appear                on                stationery used by DOLIAGE, except as a marginal note showing for                example                “Distributor for Coronado                Industries”; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.6. | interface                with customers and potential customers on behalf of CI for inquiries                with                respect to the Products and use of the                Products; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.7. | not                make claims with respect to indications for the Products that are                not                approved by the appropriate Health Authority or other appropriate                regulatory body; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.8. | purchase                sufficient quantities of the Products from CI so as to be able to                maintain                an adequate supply for resale of the                Products; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3.9. | comply                with all applicable European and French laws and regulations with                regard                to the promotion, marketing, sale and distribution of the Products,                including any reporting requirements in regards to complaints or                incidents; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.4. | promptly                report to CI, or its European representative which is                currently     Donowa                Consulting Srl    Piazza                Albania 10    00153                Rome, Italy  all                complaints, incidents or problems it receives relating to the                Products; |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.5. | follow                all CI marketing and promotion                policies. |
|--------|------|-------------------------------------------------------------------------------|

|   | 1.6. | handle                and store all Products in accordance with French and European laws                and the                labeling and instructions for the                Products. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

|   | 1.7. | CI                agrees to support DOLIAGE in the promotion, marketing, sale, distribution                and/or application for reimbursement of the Products in the Territory                and                the technical training for the employees of DOLIAGE. CI may decide,                at its                sole discretion, whether such support is possible for and available                within                CI. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.** | **SUPPLY                PRICE** |
|--------|---------------------------------|

|   | 2.1. | The                Supply Price of the Products to DOLIAGE shall be as outlined                below; |
|--------|------|-------------------------------------------------------------------------------------------------------|

|   | 2.1.1. | PNT                controllers at**[ * ]**                per controller for the first two years of the AGREEMENT. For years                three                (3) and four (4) the price will be**[ * ]**                per controller. For year five (5) until the end of the original AGREEMENT                the costs will be**[ * ]**                per controller. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.1.2. | **[                * ]**                per box of 100 rings. Each ring is individually packaged in a sterile                sachet with current labeling. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.2. | CI                will arrange for shipment of the Products from CI's manufacturing                facility                to DOLIAGE' warehouse in France. The cost of shipping the Products                from                CI's distribution facility to DOLIAGE's central receiving facility                in                France will be the responsibility of                CI. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.3. | Payment                under Clause 2.11 and 2.22 shall be Net 45 days upon delivery of                goods to                DOLIAGES' facility. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4. | The                above Supply Prices reflect the current PNT controller and PNT ring                design                and manufacturing processes. In the event the United States Food                and Drug                Administration (USFDA) or any other competent governmental health                authority (HA) requires modifications to the PNT controller and/or                the PNT                ring in order to allow continuing sale within the Territory which                would                lead to an increase in the manufacturing costs to CI of more                than**[ * ]**                ,                then CI would supply proper documentation supporting this increase,                and                the Parties agree to negotiate a new Supply Price. If DOLIAGE was                to                challenge the price increase under this clause, DOLIAGE could have                an                auditor give an independent confirmation. If the auditor found the                increase was greater than or equal to**[ * ]**                then DOLIAGE would accept the increase and pay for the audit. If                the                increase was less than**[ * ]**                then the price would remain where it was and CI would pay for the                audit. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.5. | All                Supply Prices quoted shall be understood as excluding VAT at the                statutory                tax rate or custom duties, to the extent payable. All taxes and duties                due                on the Products are the responsibility of                DOLIAGE. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.6. | DOLIAGE                will not sell materials which are provided to them free of                charge. |
|--------|------|----------------------------------------------------------------------------------------------------------|

|   | 2.7. | DOLIAGE                may return goods, including vacuum units which may require service,                to CI                only in accordance with CI's returned goods policy. Used PNT rings                cannot                be returned to CI. In general CI's returned goods policy allows for                the                return of goods which are received damaged (Section 16 below) from                CI.                Such damaged goods may be returned to CI at CI's expense. CI will                provide                shipping instructions for such returns. All other returned goods                will be                at the cost of DOLIAGE and such costs may be charged against the                PPL                (Section 5.2.2.2). |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 2.8. | CI                will warrant the controller for a period of**[ * ]**.                DOLIAGE will coordinate return of equipment under warranty, as per                the                instructions of CI, for repair or replacement. The costs of shipping                the                equipment under warranty from DOLIAGE's facility to CI's facility                will be                the responsibility of CI. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.9. | CI                will attempt to repair equipment, which is out of warranty, at the                request                of DOLIAGE. DOLIAGE will be responsible for return shipping of the                out of                warranty equipment to CI. CI will provide a cost estimate for the                repair                and will only proceed if agreed to by DOLIAGE. The cost of shipping                repaired equipment back to DOLIAGE will be born by DOLIAGE and all                costs                incurred by DOLIAGE, which are not reimbursed by DOLIAGE's customers,                associated with repair of out of warranty equipment can be charged                against                the PPL |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.10. | CI                will be responsible for the production of the Products, including                sourcing                of raw materials, CI guarantees that all Products shipped to DOLIAGE                will                be free from defects and in compliance with relevant regulatory and                governmental requirements, including compliance with the requirements                of                an EU 2a device classification and applicable cGMP Rules and will                have                sufficient expiry dating to allow for distribution through normal                distribution channels. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.** | **SALES                OF PRODUCT OUTSIDE OF                TERRITORY** |
|--------|-------------------------------------------------------------------------|

|   | 3.1. | DOLIAGE                shall not actively sell the PRODUCTS in territories or to customers                groups                which (i) CI allocated exclusively to a third party or (ii) CI reserves                for itself or for a company affiliated with                CI. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.2. | Passive                sales outside the TERRITORY and sales on part of the customers of                DOLIAGE                shall not be restricted by this                provision. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **4.** | **PROFIT                and LOSS CALCULATIONS** |
|--------|-------------------------------------------------|

|   | 4.1. | A                separate PRODUCT Profit and Loss statement (herein referred to as                the                “PPL”) will be established and maintained under this AGREEMENT. All                charges against and income credited to the PPL will be in line with                the                following guidelines. In the event that a specific charge or income                item                is not addressed below the PARTIES will discuss, in good faith, how                to                incorporate the specific item so that it is consistent and in the                spirit                of the guidelines outlined below. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.1.1. | **[                * ]**                in                support of the PRODUCTS within the TERRITORY will be born by DOLIAGE                and                included in the PPL. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.1.2. | **[                * ]**                will be credited towards the PPL. |
|--------|--------|---------------------------------------------------------------------------|

|   | 4.1.3. | DOLIAGE                will use best efforts to maximize the profits from sales of the PRODUCTS                which is credited to the PPL |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.1.4. | DOLIAGE                will not purposely offer discounts on PRODUCTS within the TERRITORY                in                order to increase sales or achieve acceptance of other products which                DOLIAGE or one of its partners sell without the written approval                of CI. In                such situations the PARTIES will agree to what additional compensation                will be credited to CI or the PPL in consideration of the discounts                that                were offered on the PRODUCTS within the                TERRITORY. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 4.1.5. | CI                will share the cost of a clinical trial**[ * ]**,                up to a maximum contribution of **[                * ]**                per year during the first two years of the contract for a total                contribution not to exceed**[ * ]**                .                Payment will be made at the end of each calendar year upon receipt                of an                invoice with sufficient detail to explain the actual costs incurred                in                performing the trial. Any payments made by CI to DOLIAGE in support                of the                clinical trial will be accounted for in the P&L and accounted for in                the calculation of any profit sharing (for example as income or an                expense                offset in the collaboration) so as to avoid an inappropriate charge                against the calculation of the profit sharing. The actual schedule                of the                clinical trial being beyond DOLIAGE's control, any delay encountered                while                undertaking the trial will be reported by DOLIAGE to CI in order                to extend                accordingly the two years time frame originally planned for CI                participation to the cost. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.2. | The                PARTIES shall agree on the marketing plan and develop a mutually                agreed                upon budget for marketing activities related to the                PRODUCTS |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.2.1. | DOLIAGE                will be responsible for all marketing costs for the PRODUCTS within                the                TERRITORY. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.2.2. | All                external costs**[ * ]**                can be charged against the PPL at full                costs |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------|

|   | 4.2.3. | **[                * ]** |
|--------|--------|--------------------------|

|   | 4.3. | DOLIAGE                will build and maintain a sales organization commensurate with the                sales                potential of the Products in the Territory and employ sales personnel                trained with sufficient product knowledge to sell the Products adequately                within the Territory; |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.3.1. | **[                * ]** |
|--------|--------|--------------------------|

|   | 4.3.2. | **[                * ]** |
|--------|--------|--------------------------|

|   | 4.4. | **[                * ]** |
|--------|------|--------------------------|

|   | 4.5. | **[                * ]** |
|--------|------|--------------------------|

----

| **5.** | **PROFIT                SHARING** |
|--------|-----------------------------------|

|   | 5.1. | Revenue                sharing shall be based on a profit sharing model as outlined                below. |
|--------|------|-----------------------------------------------------------------------------------------------------------|

|   | 5.2. | Profit/loss                from the sales of PRODUCTS will be calculated as                follows; |
|--------|------|-----------------------------------------------------------------------------------------------------|

|   | 5.2.1. | **[                * ]** |
|--------|--------|--------------------------|

|   | 5.2.1.1. | **[                * ]**  |
|--------|----------|--------------------------------|

|   | 5.2.1.2. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2. | **[                * ]** |
|--------|--------|--------------------------|

|   | 5.2.2.1. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.2. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.3. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.4. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.5. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.6. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.7. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.2.8. | **[                * ]** |
|--------|----------|--------------------------|

|   | 5.2.3. | **[                * ]**  |
|--------|--------|--------------------------------|

|   | 5.3. | **[                * ]** |
|--------|------|--------------------------|

|   | 5.4. | **[                * ]** |
|--------|------|--------------------------|

|   | 5.5. | **[                * ]** |
|--------|------|--------------------------|

|   | 5.6. | The                budget year for the PPL will coincide with DOLIAGE's budget year,                which                currently runs from October 1st                to                September 30                th                . |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.7. | DOLIAGE                will submit the final detailed PPL for the prior budget year, from                which                the profit/loss will be calculated, by October 31                st                of                the current budget year. For example, the final detailed PPL for                the                budget year October 1, 2006 to September 30, 2007 will be submitted                to CI                by October 31, 2007. CI will have the right to review the detailed                PPL and                if they disagree with specific aspects of PPL can request that they                be                adjusted. For the budget period from contract initiation until September                30, 2006 the PPL will be prepared and agreed to by May 30,                2006. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 5.8. | In                the event that the PARTIES cannot agreed on whether a specific charge                or                income item should be included on the PPL, the PARTIES will have                an                independent auditor, acceptable to both PARTIES with such acceptance                not                to be unreasonably withheld, review the PPL and render a decision                on                whether the charge is valid. The PARTIES will share the costs of                the                audit |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.9. | CI                can request once a year that an independent auditor, acceptable to                both                PARTIES with such acceptance not to be unreasonably withheld, review                the                entire PPL and all supporting documentation to verify that the PPL                was                prepared in compliance with this AGREEMENT. If it is found that additional                monies are owed CI as a result of the audit then DOLIAGE will pay                the                additional funds. If the amount of the additional monies owed CI                is                greater than 10% of the monies originally calculated in the PPL the                costs                of the external auditor will be borne by DOLIAGE otherwise the costs                of                the external auditor will be the responsibility of CI. DOLIAGE will                provide its own resources for such audit at no cost. Reasonable advance                notice should be given by CI of its intention to perform such an                audit,                and reasonable usage of DOLIAGE resources will be made, so as not                to                affect DOLIAGE's operation. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.10. | The                PARTIES will use best efforts to finalize and close the PPL for the                prior                budget year by December 1st                of                the current budget year. For example, the PPL for the period October                1                st,                2006, to September 30th, 2007 should be finalized and closed by December                1                st                ,                2007. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.11. | **[                * ]** |
|--------|-------|--------------------------|

| **6.** | **BUDGETS** |
|--------|-------------|

|   | 6.1. | DOLIAGE                will prepare a budget in line with the Sales and Marketing plan agreed                to                by the PARTIES. The PARTIES must mutually agree and approve each                annual                budget by December 31                st                of                the prior year. For example the annual budget for the period October                1                st                2006 to September 30                th                2007 should be approved by December 31                st                ,                2006. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.2. | If                the PARTIES do not agree on the budget submitted by DOLIAGE the PARTIES                will discuss in good faith such differences and utilize best efforts                to                reach agreement on the annual                budget. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **7.** | **FORECASTING** |
|--------|-----------------|

|   | 7.1. | On                the first day of each calendar quarter, DOLIAGE shall provide CI                with a                written rolling forecast of the requirement for the Products, per                month,                for the then current calendar quarter and the next 3 (three) calendar                quarters. The forecast for the then current calendar quarter shall                be                binding, for the remaining calendar quarter's                non-binding. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.2. | At                least three (3) months in advance of the requested delivery date                of the                Products, DOLIAGE shall submit to CI a written purchase order for                the                desired quantities of the Products (hereinafter referred to as “Purchase                Order”). All Purchase Order shall be firm and binding upon the Parties                and                shall bear the exact quantity ordered and the agreed upon delivery                date. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **8.** | **RELATIONSHIP                OF THE PARTIES** |
|--------|------------------------------------------------|

| **9.** | **NOTICES** |
|--------|-------------|

| If                to DOLIAGE:  | Laboratories                DOLIAGE           |
|--------------------------------|----------------------------------------------------|
|                           | 81                rue de Verdun,              |
|                           | 92150                Suresnes,                |
|                           | France                                        |
|                           | Facsimile:                (33) 1 41 38 29 55  |
|                           | Attention:                CEO                 |
|                           |                                               |
| If                to CI:  | Coronado                Industries            |
|                           | 16857                Saguaro Blvd             |
|                           | Fountain                Hills, Arizona 85268  |
|                           | USA                                                |
|                           | Attention:                CEO                      |
|                           | CC: Director                of Operations     |
|                           | Facsimile                +1 480 837 6870           |

| **10.** | **FORCE                MAJEURE** |
|---------|----------------------------------|

 

----

| **11.** | **TRADEMARKS                AND PATENTS** |
|---------|-------------------------------------------|

|   | 11.1. | CI                will be responsible for registering and maintaining all applicable                Patents                within the Territory as listed in Schedule B (hereinafter referred                to as                “Patents”) relating to the Products in the Territory at CI's                costs. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.2. | By                virtue of the Agreement and DOLIAGE's performance hereunder, DOLIAGE                shall                acquire no interest in CI trademarks or corporate names, label designs                or                other identifying marks used to distinguish CI's Products. Except                for                undertaking such activities as are directly related to promoting                the sale                of the Product under this Agreement, DOLIAGE shall not make use of                the                name CI, or make use of any trademark or trade name which in the                judgment                of CI is confusingly similar thereto without the written consent                of                CI. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.3. | The                Parties will use their best efforts to discover any infringement                of any                Patent, Trademark or corporate name of Coronado Industries and will                promptly notify each other of any such infringement or wrongful use.                Any                Proprietary Information provided shall be and remain the property                of CI,                and CI will impose any conditions with respect thereto which it deems                reasonably necessary to preserve the confidential nature thereof.                DOLIAGE                will retain all Proprietary Information in strict confidence as trade                secrets of CI and will not disclose, or permit any employee or agent                of                DOLIAGE to disclose, any Proprietary Information to anyone without                the                prior written approval of CI, provided, however, that such disclosure                may                be made to any employee of DOLIAGE who has a reasonable need for                access                thereto. For the purpose of this Agreement, the term “Proprietary                Information” shall mean all formulae, processes, and other information                relating to the distribution, sale, and use of any Product which                has been                or may hereafter be furnished to DOLIAGE and which would not be available                to the general public otherwise than through violation of this                Agreement. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.4. | CI                shall use its best efforts so that DOLIAGE will not incur any claim                of                patent infringement as a result of distribution of the Products within                the                Territory under this Agreement. If such claims arise, and are attributable                to the actions of DOLIAGE allowed under this Agreement, CI will at                its own                costs use reasonable efforts to interfere and resolve the issue.                DOLIAGE                will notify CI immediately of any claims of patent infringement.                Any                liability for damages from an infringement as a direct result of                the sale                of the Products by DOLIAGE under the terms of this Agreement, will                be the                responsibility of CI. DOLIAGE will cooperate fully with CI to resolve                and/or defend against any claim of infringement under this                Agreement. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.5. | If                DOLIAGE is aware of a patent infringement on its territory, DOLIAGE                will                inform CI, and CI will at its own cost take any action to protect                the                patent rights. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.6. | Upon                the expiration or prior termination of this Agreement, DOLIAGE will                exercise all necessary precautions to safeguard the secrecy of Proprietary                Information and to prevent the unauthorized disclosure thereof, DOLIAGE                will consult CI as to the procedures established by it for this purpose                and will from time to time, if requested by CI, advise CI of the                procedures which it then has in                effect. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **12.** | **REGISTRATIONS                AND HEALTH AUTHORITY                INTERACTIONS** |
|---------|-----------------------------------------------------------------------------------|

|   | 12.1. | CI,                with the assistance of DOLIAGE, will be responsible for all interactions                with the relevant Health Authorities (HA's), including but not limited                to                the Type 2a device classification filling of the Product and any                maintenance of the Type 2a filling with the relevant                authorities. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

|   | 12.2. | DOLIAGE                will bear the costs associated with any additional registration(s)                with or                applications to the relevant Health Authority(s) within in the Territory                which are required to sell the                Products. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.3. | DOLIAGE,                as reasonably requested by CI, will assist, provide expertise and                interact                as required in dealing with the relevant HA's in the                Territory. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.4. | CI                and DOLIAGE agree that a Type 2a device classification is required                to                allow the sale of the Products in the Territory. CI agrees to supply                DOLIAGE with Products meeting this classification and will not knowingly                or negligently ship Products which does not meet this                classification. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **13.** | **CLINICAL                TRIAL** |
|---------|-----------------------------------|

|   | 13.1. | DOLIAGE                will be allowed to perform, in collaboration with CI, clinical trials                in                order to enhance the marketability of the PRODUCTS within the                TERRITORY |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.2. | The                clinical trials will involve up to 2/4 centers and approximately                100                patients. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------|

|   | 13.3. | The                protocols for the clinical trials will be approved by both Parties                and                respective Ethical Committees prior to initiation of the                study. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.4. | The                costs of performing the clinical trial will be born by DOLIAGE. CI                will                reimburse DOLIAGE as outlined Section 4.1.5                above |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.5. | DOLIAGE                will have in place confidentiality agreements with all clinicians                involved                with the clinical trial. DOLIAGE will do its best to prevent any                non-agreed dissemination regarding the clinical trial or its results                without the prior consent of CI. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.6. | All                information developed as part of the clinical trial will be considered                as                Confidential Information (as defined below under Section 14) and                cannot be                used for any other purpose by DOLIAGE other than to promote the Products                in a way which is beneficial for the Product. In the event the AGREEMENT                is terminated then all information collected under this Agreement,                including the information gathered as part of the clinical trial                will                become the property of CI. DOLIAGE also acknowledges that it will                not use                any of the information obtained under this Agreement, including                information obtained as part of the clinical trial, to promote another                device which would compete with the                PRODUCTS. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **14.** | **TERM                AND TERMINATON** |
|---------|----------------------------------------|

|   | 14.1. | The                term of this Agreement shall be for a period of eight (8) years from                the                Effective Date of this Agreement (hereinafter referred to as “Initial                Term”). Following the Initial Term outlined above, this Agreement will                be                automatically renewable on an annual basis, unless either Party notifies                the other 6 months prior to expiration of the Initial Term, or each                annual                extension, of their intention not to                renew. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

|   | 14.2. | If                DOLIAGE's cumulative losses, which will be calculated as their costs                directly associated with the AGREEMENT less any monies from the envisioned                profit share, over the first two years of the AGREEMENT exceed 150,000                Euros DOLIAGE will have an option to request a renegotiation of the                AGREEMENT and if CORONADO declines to terminate the                AGREEMENT |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.3. | CI                shall have the option to terminate, upon ninety (90) days' written                notice,                if ownership or control (for example. greater than 50.01 % of the                shares)                of DOLIAGE is transferred to a third party, which is considered by                CI to                be detrimental for CI's interests. Either Party may terminate this                Agreement if the other Party is adjudged bankrupt, files or has filed                against it any petition under any bankruptcy or insolvency law, has                a                receiver appointed for its business or property, or makes a general                assignment for the benefit of its                creditors. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.4. | DOLIAGE                hereby accords CI upon termination or expiration of this Agreement                an                option to repurchase from DOLIAGE all or any part of DOLIAGE' inventory                of                that Products, which DOLIAGE will not need in order to fulfill its                delivery commitments towards its customers for commitments which                can be                documented were made prior to termination of expiration of this Agreement                (hereinafter referred to as “Inventory Products”), at the price paid                therefore by DOLIAGE (hereinafter referred to as “Repurchase Price”),                pursuant to the following                procedures: |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.4.1. | Within                five (5) days after the effective date of termination, DOLIAGE shall                submit to CI a written schedule reflecting all Inventory Products                then                owned by or in DOLIAGE' possession. Said schedule shall identify                each                Inventory Product and shall indicate the quantity thereof on                hand. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.4.2. | Within                ten (10) days after the receipt of such schedule by CI, CI shall                have the                right to inspect the inventory reflected on such                schedule. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.4.3. | Within                five (5) days after completion of CI's inspection of said inventory,                CI                shall give written notice of its election to repurchase all or any                part of                the Inventory Products. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.4.4. | Upon                receipt of said notice of repurchase, DOLIAGE shall forthwith deliver                such                Inventory Products as may be specified therein to a carrier designated                by                CI and at the costs of CI. Payment of the Repurchase Price as hereinabove                provided shall be made by CI to DOLIAGE within five (5) days after                the                delivery of said Products to                carrier. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.5. | Upon                termination or expiration of this Agreement, DOLIAGE shall immediately                cease to represent itself as an authorized distributor of CI with                respect                to the Products. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.6. | CI                can elect, but will have no obligation, to provide additional product                in                order to allow DOLIAGE' to fulfill commitments towards its customers                following termination or expiration of this                Agreement. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.7. | The                termination or expiration of this Agreement shall not release either                Party                from the obligation to pay any sum that may be owing to the other                Party or                operate to discharge any liability that had been incurred by either                Party                prior to any such termination. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

|   | 14.8. | Failure                by a Party to comply with any of its material obligations contained                in                this Agreement, including payment term obligations, shall entitle                the                non-defaulting Party to give to the defaulting Party written notice                specifying the nature of the default and requiring the defaulting                Party to                make good such default. If such default is not cured within sixty                (60)                days after the receipt of such notice (or, if such default is not                capable                of being cured within such sixty (60) day period, within such amount                of                time as may be reasonably necessary to cure such breach, as long                as the                Defaulting Party is making diligent efforts to do so, except in the                case                of payment default, as to which the defaulting Party shall have only                a                sixty (60) day cure period), the non-defaulting Party shall be entitled                immediately to terminate this Agreement by giving written notice                to the                defaulting Party. The right of a Party to terminate this Agreement,                as                hereinafter provided, shall not be affected in any way by its waiver                or                failure to take action with respect to any previous                default. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.9. | The                Parties may agree in writing, signed by both Parties, to terminate                this                Agreement in its entirety. In such an event, the Parties shall agree                to                the effects of such termination at that                time. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.10. | If                the PARTIES cannot agree on the annual budget as outlined under Clause                6                by November 15th                of                the prior year then either PARTY may elect to terminate this                AGREEMENT. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 14.11. | In                the event this AGREEMENT is terminated under clause 14.10 above then                Clauses 14.4, 14.4.1, 14.4.2, 14.4.3, 14.4.4, 14.4.5, 14.5, 14.6                and 14.7                will apply. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.** | **CONFIDENTIALITY** |
|---------|---------------------|

| **16.** | **ASSIGNMENT** |
|---------|----------------|

|   | 16.1. | This                Agreement shall be binding upon the successors and assignees of CI                and                DOLIAGE. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------|

|   | 16.2. | Either                Party may assign this Agreement to a wholly owned subsidiary or other                entity in which the transferring Party has a majority share and                operational control. In case of such an assignment, the assigning                party                will remain jointly and severally liable for all of its obligations                under                this Agreement. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 16.3. | This                Agreement shall not be assignable by either Party to an independent                third                party, without the prior written consent of the other Party, such                consent                not to be unreasonably withheld. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **17.** | **INDEMNIFICATION                / DEFECTS OF THE PRODUCTS** |
|---------|--------------------------------------------------------------|

|   | 17.1. | CI                will indemnify, defend and hold harmless DOLIAGE from any and all                liability, loss, or damage DOLIAGE may suffer as a result of claims,                demands, costs, or judgment against it arising from product liabilities                of                any kind under any jurisdiction provided that such product liability                is                not based on DOLIAGE' negligence in storing, maintaining, labeling,                promoting or selling the Products or otherwise failing to comply                with                applicable laws and regulations and the terms of this Agreement.                In the                latter case, DOLIAGE will indemnify, defend and hold harmless CI                from any                and all liability, loss or damage CI may suffer as a result of such                claims, demands, costs or judgments against                it. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

|   | 17.2. | For                the duration of this Agreement, each Party will maintain, at each                Party's                own expense, insurance coverage from a reputable insurance carrier                in the                amount of a minimum of USD $1.0 million per incidence. Upon request                of a                Party, the other Party shall submit a copy of the respective certificate                of insurance. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.3. | DOLIAGE                shall inspect the delivered Products immediately following delivery                by CI                insofar it is practicable in the orderly course of business and notify                apparent defects to CI within 14 days after their discovery. All                other                defects, such as hidden defects, will be notified by DOLIAGE within                14                days after their discovery. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.4. | If                (i) the Products delivered by CI are agreed by the Parties to be                defective                and/or (ii) if it turns out and the Parties agree that the Products                were                damaged prior to receipt by DOLIAGE and/or (iii) the Parties agree                that                the Products do not have the agreed upon quality, DOLIAGE shall have                the                right to request defect-free goods as replacement. In the event that                CI                cannot deliver within 45 days following notification by DOLIAGE and                agreement between the Parties that the Products are defective as                described                under (i) - (iii) above DOLIAGE will have the right to cancel the                respective individual orders involving the above goods and receive                a                refund of any monies paid to CI. Removal and return deliveries of                defective Products shall be effected at CI ́s costs and                risk. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **18.** | **MISCELLANEOUS** |
|---------|-------------------|

|   | 18.1. | The                provisions of this Agreement shall be construed and the performance                thereof governed in accordance with the laws of the State of New                York,                USA. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.2. | All                sub-distributors selected by DOLIAGE must be pre-approved by CI.                The                consent of CI shall not be unreasonably withheld. In the event that                DOLIAGE becomes aware that a sub-distributor is in violation of any                part                of this Agreement DOLIAGE will immediately inform CI and will take                all                necessary actions to ensure compliance with this Agreement by the                sub-distributor. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.3. | The                article headings in this Agreement are inserted for convenience only                and                shall not be deemed to be part of this Agreement or considered in                construing this Agreement. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.4. | This                Agreement constitutes the entire understanding between the Parties                and                supersedes any previous written or oral agreements or understandings                between the Parties. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.5. | No                modification to or waiver of the terms or conditions hereof shall                be                binding upon either Party unless approved in writing by an authorized                representative and no modification can be made by the acknowledgment                of                acceptance or by the use of purchase order forms containing other                or                different terms or conditions. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.6. | This                Agreement may be executed in one or more counterparts, each of which                shall                be deemed an original but all of which shall constitute one and the                same                instrument. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

|   | 18.7. | Should                the effects of this Agreement resulting from future unforeseen events                and                developments lead to an unjust hardship for either Party and which                hardship does not correspond with the intention of the Parties in                good                faith, the Parties shall without delay enter into negotiations to                see in                what way the conditions of the Agreement can be modified to suit                altered                circumstances. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.8. | Neither                the general terms of sale and delivery of CI nor the general terms                of                purchase of DOLIAGE shall apply to this Agreement or the individual                transactions concluded on its basis. This shall also apply if either                Party                refers to its general terms and conditions when concluding an individual                transaction. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.9. | All                disputes arising out of or in connection with this Agreement shall                first                be attempted to be settled between the Parties on a good faith basis.                If                the Parties are unable to resolve the dispute within 60 (sixty) days                from                the receipt by one Party of the other Party's written notice asking                for                such amicable settlement discussions, then such dispute shall be                finally                settled by arbitration in accordance with the International Chamber                of                Commerce (ICC) Rules of Arbitration by three arbitrators, appointed                in                accordance with said rules. The place of arbitration shall be New                York                City, New York, USA. The proceedings shall be conducted and all                documentation shall be presented in                English. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

| **19.** | **SCHEDULES** |
|---------|---------------|

|   | 19.1. | Schedule                A:   Products |
|--------|-------|------------------------------------------------------|

|   | 19.2. | Schedule                B:    Patent |
|--------|-------|----------------------------------------------------------|

**IN      WITNESS THEREOF**

| **CORONADO                INDUSTRIES, Inc.**  |      | **Laboratories                DOLIAGE** |
|----------------------------------------------------|-----------|-----------------------------------------|
|                                               |      |                                    |
| By:                                      | /s/  |                                    | By:   | /s/  |
|                                               | NameTitle |                                    |   | NameTitle |
|                                               |      |                                    |   |   |

----

**SCHEDULE      A**

| Products  |   |                                                                                                                                                                                                              |
|----------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |   | PNT                Vacuum Controller - Model 1000                                                                                                                                                                 |
|           |   |                                                                                                                                                                                                              |
|           |   | PNT                Sterilized/Single Use/Disposable Ring - pre-sterilized polypropylene                3-port PNT ring. One (1) sterilized ring per sealed Tyvek® pouch. 100                rings per carton |

----

**SCHEDULE      B**

| Patents  |   |                                                                                                                   |
|---------------|--------|------------------------------------------------------------------------------------------------------------------------|
|          |   | Patent                Number 0790803 `Open Angle Glaucoma Treatment Apparatus' issued February                19, 2003 |

 

----